公司資料
Ardelyx 股價、新聞與催化劑
- 股票代碼:
- ARDX
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
4.06 USD (0.00%)
收盤價
最後更新: 2026年8月17日
1.36B USD
市值
股價為何變動
As of Aug 17, 2026, ARDX was little changed and closed at $4.06. No new same-company headline was identified in the current news window.
公司概覽
NHE3 Inhibition Platform
Ardelyx develops and commercializes medicines based on inhibition of the sodium-hydrogen exchanger 3 in the gastrointestinal tract. Its approach changes intestinal sodium transport and can affect bowel function and phosphate absorption.
IBSRELA and XPHOZAH
IBSRELA is approved for irritable bowel syndrome with constipation, while XPHOZAH is approved to lower serum phosphorus in adults with chronic kidney disease on dialysis who have an inadequate response or intolerance to phosphate binders. Both products contain tenapanor.
Pipeline Expansion
The Phase 3 ACCEL trial is evaluating IBSRELA in adults with chronic idiopathic constipation. RDX10531 is a next-generation NHE3 inhibitor being explored across additional therapeutic applications.
未來催化劑
- Completion of enrollment in the Phase 3 ACCEL trial expected by year-end 2026.
- Topline ACCEL results expected in the second half of 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。